Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

OBJECTIVE: Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and maintenance treatment in patients with moderate-to-severe Crohn's disease (CD). DESIGN: We conducted two randomised,...

Descripción completa

Detalles Bibliográficos
Autores principales: Panés, Julian, Sandborn, William J, Schreiber, Stefan, Sands, Bruce E, Vermeire, Séverine, D'Haens, Geert, Panaccione, Remo, Higgins, Peter D R, Colombel, Jean-Frederic, Feagan, Brian G, Chan, Gary, Moscariello, Michele, Wang, Wenjin, Niezychowski, Wojciech, Marren, Amy, Healey, Paul, Maller, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532457/
https://www.ncbi.nlm.nih.gov/pubmed/28209624
http://dx.doi.org/10.1136/gutjnl-2016-312735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532457/
https://www.ncbi.nlm.nih.gov/pubmed/28209624
http://dx.doi.org/10.1136/gutjnl-2016-312735

Ejemplares similares